[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-infarction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,42,98,133,157,193,218,245,268,294,323,347,374,405,430,454,483,510,536,562,587,618],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100622097","phase-3-hr-mri-directed-tirofiban-therapy-for-late-window-acute-ischemic-stroke-tian-100622097",false,"NCT07379190","HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Acute ischemic stroke (AIS) in the anterior intracranial circulation (internal carotid artery system) confirmed by clinical symptoms and imaging examinations;\n3. Time from symptom onset or last known normal state to randomization: \\> 24 hours and ≤ 7 days;\n4. Stroke subtype confirmed as intracranial large artery atherosclerosis (ICAS) by high-resolution vessel wall imaging (HR-VWI) according to the TOAST classification, with cardiogenic embolism and other etiologies excluded;\n5. Baseline National Institutes of Health Stroke Scale (NIHSS) score of 4-20 at the time of randomization;\n6. Signed informed consent form obtained from the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Planned to receive reperfusion therapy (endovascular therapy or intravenous thrombolysis)；\n2. Intracranial hemorrhage confirmed by computed tomography (CT)；\n3. Definite or suspected cardiogenic embolism；\n4. History of atrial fibrillation or current electrocardiogram indicating atrial fibrillation；\n5. Acute ischemic stroke caused by other etiologies, such as Moyamoya disease, arterial dissection, arteritis, etc；\n6. Imaging examinations indicating that the area of the current cerebral infarction exceeds 1\u002F2 of the area of a single cerebral lobe;\n7. Known contraindications to antiplatelet therapy, including hematochezia, gastrointestinal bleeding, or any other hemorrhagic disorders;\n8. History of hypersensitivity to aspirin;\n9. Definite indication for anticoagulant therapy expected during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state, etc.);\n10. Complicated with malignant tumors, chronic hemodialysis, severe renal insufficiency (glomerular filtration rate \\[GFR\\] \\\u003C 30 ml\u002Fmin or serum creatinine \\[Cr\\] \\> 220 μmol\u002FL (2.5 mg\u002Fdl)), or severe hepatic insufficiency (serum alanine aminotransferase \\[ALT\\] \\> 2 times the upper limit of normal \\[ULN\\], or serum aspartate aminotransferase \\[AST\\] \\> 2 times the ULN);\n11. Severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification Class III or IV);\n12. Complicated with severe non-cardiovascular comorbidities, with an estimated survival time \\\u003C 6 months;\n13. Concurrent new cerebral infarction in both anterior and posterior circulations;\n14. Inability to complete the follow-up procedures;\n15. Presence of other known neurological disorders that may complicate the follow-up;\n16. Concurrent participation in other therapeutic clinical trials with incomplete treatment and follow-up;\n17. Other conditions that the investigators consider inappropriate for enrollment in this study.","ALL","18 Years",{"count":19,"type":20},458,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study aims to address the existing clinical challenges by introducing high-resolution magnetic resonance vessel wall imaging (HR-MRI), an advanced imaging technology, to achieve precise etiological classification in patients with acute ischemic stroke (AIS) beyond the time window. HR-MRI allows clear visualization of intracranial arterial wall structures and direct identification of key pathological features of the culprit vessel, including atherosclerotic plaques, vascular wall remodeling, and intracranial hemorrhage, thereby enabling reliable differentiation between intracranial atherosclerotic large artery atherosclerosis (ICAS-LAA) stroke and other etiological subtypes such as cardiogenic embolism. Based on the latest clinical demands and advances in imaging technology, this study intends to evaluate the efficacy and safety of tirofiban in patients with ICAS-LAA stroke beyond the time window under the precise guidance of HR-MRI. It is expected to provide high-level evidence-based medical evidence for this specific patient population and further optimize clinical diagnosis and treatment strategies.",[26,27,28],"Stroke, Acute","Stroke, Ischemic","Cerebral Infarction","RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2026-06-22",{"date":37,"type":20},"2029-05-01",{"name":39,"class":40},"Weifang Medical University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100270060","neurologic-stem-cell-treatment-study-100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.",{"count":51,"type":20},500,[53],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[56,57,58,59,60,61,62,63,28,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[82,83,60,61,84,85,73,86,64,79,76,87],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration",{"date":89,"type":33},"2026-06-26",{"date":91,"type":33},"2016-06",{"date":93,"type":20},"2028-07-31",{"name":95,"class":96},"MD Stem Cells","INDUSTRY",3,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":41},"100553492","phase-4-stroke-prevention-in-ischemic-stroke-with-covert-atrial-fibrillation-100553492","NCT06486792","Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation","SPICAF","Inclusion Criteria:\n\nIncluded patients must fulfill the following 4 criteria:\n\n1. patient aged ≥65 years with:\n\n   1. recent (\\\u003C15 days) cerebral infarction\n   2. with cerebral ischemia proven on MRI or head-CT\n2. with no known atrial fibrillation before stroke and no atrial fibrillation detected during hospital stay (monitoring or telemetry) and no mural thrombus.\n3. but with suspected atrial fibrillation:\n\n   1. multiple territorial (i.e., in the territory of a cerebral artery or one of its branches) cerebral infarctions in several arterial territories involving both hemispheres, or in the same hemisphere, or in both anterior and posterior circulation, symptomatic or not\n   2. or a single cerebral infarction and systemic emboli (e.g., renal, splenic, hepatic or mesenteric infarction, peripheral emboli in arm or leg), symptomatic or not\n   3. or any ischemic stroke with dilation of atrium (\\>34 mL\u002Fm²) or left atrial spontaneous echocardiographic contrast or LAA velocities \\\u003C 40 cm\u002Fsec or pro BNP \\> 400 pg\u002FmL or left ventricular ejection fraction (LVEF) \\\u003C 40% or supraventricular extrasystole ≥ 400\u002F24 h or longest \"atrial run\" ≥ 20 beats on telemetry\n   4. or age ≥80 year-old and a single infarction\n4. and a plan to detect atrial fibrillation with, long term Holter ECG, wearing device or implantable loop recorder\n5. with a Rankin score equal or less than 4\n6. patient has signed an informed consent\n7. Patient is affiliated to a social security.\n\nExclusion Criteria:\n\n1. Patients with a known cause of stroke, using ASCOD classification A1, C1, S1, O1, D1\n2. Symptomatic brain hemorrhage (the mere presence of microbleeds on gradient echo imaging is not an exclusion criteria)\n3. Uncontrolled hypertension (following the judgment of the investigator)\n4. Clear indication to anticoagulant or antiplatelet therapy\n5. Contra-indication to anticoagulant or antiplatelet therapy\n6. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits\n7. Participation in another interventional clinical trial.\n8. Under contraception in case of childbearing potential\n9. Patient under guardianship or curatorship","65 Years",{"count":107,"type":20},1148,[109],"PHASE4","Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay. After discharge, these patients are typically monitored for AF using devices like Holter monitors or implantable loop recorders. Treatment options during this period include anticoagulants or aspirin. Anticoagulants are more effective in preventing recurrent strokes if AF is present, offering an 80% risk reduction compared to aspirin's 20%. If AF is detected, anticoagulant treatment continues; if not, patients may switch to aspirin after 6-12 months. Despite the clinical rationale for using anticoagulants during this search period, their benefit-risk ratio compared to aspirin has not been fully evaluated.",[60,112,28,113],"Ischemic Stroke","Atrial Fibrillation",[60,112,115,113,116,117,118,119,120,121,122,123],"Cerebral infarction","Anticoagulant","Aspirin","Prevention stroke","AVK","Apixaban","rivaroxaban","dabigatran","ECG","2026-06-03",{"date":126,"type":33},"2026-06-05",{"date":128,"type":33},"2025-06-18",{"date":130,"type":20},"2028-12-18",{"name":132,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":41},"100636283","phase-4-early-low-dose-aspirin-use-after-intravenous-thrombolysis-for-acute-ischemic-cerebral-infarctionelastic-100636283","NCT07563673","Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction（ELASTIC）","Safety and Efficacy of Treatment With Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction (ELASTIC): A Randomized, Open-label, Blinded Endpoint, Clinical Trial","ELASTIC","Inclusion Criteria:\n\n1. Age range: 18-65 years old\n2. Receive rt PA thrombolytic therapy within 3 hours (including 3 hours) of onset\n3. Signs of brain dysfunction lasting for more than 1 hour\n4. CT imaging excludes cerebral hemorrhage, and there are no imaging changes corresponding to the patient's physical signs\n\nExclusion Criteria:\n\n1. Age\\>65 years old\n2. Onset time\\>3 hours\n3. Accompanied by consciousness disorders, or NIHSS ≥ 20 points\n4. CT shows' high-density shadow of middle cerebral artery '\n5. Accompanied by atrial fibrillation or clearly identified as cardioembolic embolism\n6. Severe swallowing difficulties, unable to take medication orally\n7. Oral anticoagulant medication is currently being taken\n8. Accompanied by severe infection or evidence of severe infection\n9. Refusal to sign the informed consent form for this study\n10. Exclusion criteria for other traditional intravenous thrombolysis",{"count":142,"type":20},210,[109],"This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.",[28,146],"Thrombolysis","NOT_YET_RECRUITING","2026-05-05",{"date":150,"type":33},"2026-05-08",{"date":152,"type":20},"2026-05-01",{"date":154,"type":20},"2027-12-31",{"name":156,"class":40},"Beijing Chao Yang Hospital",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":4},"100631057","phase-1-safely-quenching-complement-in-stroke-survivors-100631057","NCT07495722","Safely Quenching Complement in Stroke Survivors","Safely Quenching Complement in Stroke Subjects: A Phase 1 Safety Trial","SUCCESS","Inclusion Criteria:\n\n* Adults (18-80 years old)\n* Diagnosis of AIS due to anterior circulation (Intracranial ICA, M1 MCA) LVO with evidence of complete\u002Fnear-complete revascularization following EVT (mTICI ≥2b).\n* Enrollment within 24 hours of reperfusion, with reperfusion occurring within 24 hours of ictus onset.\n* Body weight ≥ 50 kg.\n* Absolute reticulocyte count \\>1.0 x ULN\n* Platelet count of \\>50,000\u002Fmm³\n* Absolute neutrophil count (ANC) ≥ 1500\u002Fmm³ at\n* Vaccination against Neisseria meningitidis types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day1 dosing, or within 14 days after EMPAVELI. Unless documented evidence exists, that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits\n* Women of child-bearing potential (WOCBP) must have a negative pregnancy test and must agree to use protocol defined methods of contraception for the duration of the study and 90 days after study drug administration.\n* Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study and 90 days after study drug administration.\n* English\u002FSpanish-speaking patients or legally authorized representatives (LARs).\n* Signed informed consent from the patient or LAR.\n\nExclusion Criteria:\n\n* Pregnant or lactating female\n* Suspected pregnancy.\n* Renal insufficiency (GFR\\\u003C30mL\u002Fminute OR creatinine \\>2 mg\u002FdL OR need for renal replacement therapy (RRT) at time of admission).\n* Platelet count \\\u003C 50,000\u002Fmm³\n* Absolute neutrophil count \\\u003C1500\u002Fmm³\n* Baseline mRS \\>2\n* Presence of concomitant serious illness that would confound study, including but not limited to serious psychiatric or autoimmune disease, sepsis, or trauma.\n* Immunocompromised status (e.g., subjects with Human Immunodeficiency Virus \\[HIV\\] infection, neutropenia, complement deficiency, etc.)\n* Autoimmune disorder (Sjogren's Disease, Psoriasis, hediak-Higashi Syndrome)\n* Presence of any intracranial bleed (ICH, SAH, SDH, hemorrhagic lesion).\n* Active hepatic failure as defined by AST \\>160 units\u002FL and\u002For ALT \\>180 units\u002FL, or total bilirubin levels greater than four times normal levels (\\>4.8mg\u002FdL).\n* Continued use of digoxin or amlodipine (as recommended by the manufacturer due to CYP3A inhibition).\n* Patients with DNR orders.\n* Known infection at the time of admission (elevated WBC with identified infection source)\n* Evidence of blood dyscrasia.\n* Episode of fever \\> 38.5 degrees Celsius during admission and prior to enrollment.\n* History of any clinically significant disease or disorder which, in the opinion of the Investigator, could have either put the subject at risk because of participation in the study, or interfered with interpretation of the subject's study results","80 Years",{"count":167,"type":20},20,[169],"PHASE1","This study will include adults (ages 18-80) who have had a stroke caused by a large blood clot blocking blood flow in the brain. All patients in the study must have already had a treatment called a thrombectomy, where doctors remove the clot to help blood flow return to the brain.\n\nThe goal of this study is to test the safety of a drug called EMPAVELI (pegcetacoplan). This drug is meant to lower swelling and inflammation that can happen after blood flow returns. The hope is that it may help protect the brain from more damage and improve recovery.\n\nPeople in the study will get three doses of EMPAVELI through an EMPAVELI-designed pump 0-3 hours post thrombectomy surgery and 24 and 48 hours after the initial dose. Doctors will check them with exams, blood tests, brain scans, and other tests while they are there. Patients will also have follow-up visits at 30 and 90 days to see how they are doing, per the usual standard of care.\n\nThis research is important because, even with current stroke treatments, many patients still have problems like disability. If this drug is found to be safe, it could lead to better treatments to protect the brain and help people recover more fully after a stroke.",[172,28],"Acute Ischemic Stroke",[174,175,176,177,178,179,180,181,182,183],"endovascular thrombectomy","large vessel occlusion","reperfusion injury","complement inhibition","C3 inhibition","pegcetacoplan","empaveli","neuroprotection","thromboinflammation","stroke recovery","2026-04-24",{"date":186,"type":33},"2026-04-29",{"date":188,"type":20},"2026-10",{"date":190,"type":20},"2027-08",{"name":192,"class":40},"Columbia University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":201,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":217},"100574321","phase-4-the-effect-and-safety-of-combined-anti-platelet-treatment-in-acute-ischemic-stroke-due-to-large-artery-atherosclerosis-100574321","NCT06757764","The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","The Effect and Safety of Therapy Adding Cilostazol in Acute Ischemic Stroke Due to Large Artery Atherosclerosis: CHANGE Trial","CHANGE","Inclusion Criteria:\n\n1. Age of 20 years or older\n2. Acute ischemic stroke due to large artery atherosclerosis (both including Intra and extracranial atherosclerosis) which may be defined by a ischemic lesion confirmed at diffusion-weighted image and a corresponding significant stenosis (more than 50% of diameter reduction) proximal to the ischemic lesion confirmed by MR angiography or CT angiography.\n3. Informed consent obtained within 72h from stroke onset\n4. Acquisition of written informed consent prior to study entry\n\nExclusion Criteria:\n\n1. Large infarction unable to start antiplatelet treatment\n2. Combined with acute intracranial haemorrhage\n3. With initial haemorrhagic transformation\n4. Previous mRS higher than 2\n5. Indicated for anticoagulation\n6. Contraindication for aspirin, clopidogrel or cilostazol\n7. Requirement of long term NSAID\n8. Pre-planned for surgery\n9. Unable to withdraw consent\n10. Unavailable to participate based on judgement of the investigator\n11. Participants of reproductive potential (PORP)\u002F Participants of childbearing potential (POCBP) who do not agree to practice methods of birth control or remain fully abstinent from sexual activity with the potential for conception.","20 Years",{"count":203,"type":20},2340,[109],"Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.",[28,207],"Stenosis Artery","2026-03-25",{"date":210,"type":33},"2026-03-27",{"date":212,"type":33},"2025-07-10",{"date":214,"type":20},"2028-03-31",{"name":216,"class":40},"Asan Medical Center",24,{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":21,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":244},"100558273","phase-3-early-antiplatelet-administration-after-intravenous-thrombolysis-for-acute-ischemic-stroke-trend-ivt-100558273","NCT06548971","Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)","Safety and Efficacy of Treatment With Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): A Multicenter, Randomized, Placebo-controlled, Clinical Trial","TREND-IVT","Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. Acute ischemic stroke treated with intravenous thrombolysis with alteplase or tenecteplase within 4.5 hours of onset or time last known well, and can receive the study drug treatment within 3 hours of initiating intravenous thrombolysis.\n3. Residual NIHSS score \\> 5 points assessed 1 hour after initiation of intravenous thrombolysis and prior to randomization.\n4. Informed consent obtained from patients or an authorized representative.\n\nExclusion Criteria:\n\n1. Stroke caused by definite large vessel occlusion (including A1\u002FA2 segments of the anterior cerebral artery, M1\u002FM2 segments of the middle cerebral artery, P1\u002FP2 segments of the posterior cerebral artery, intracranial\u002Fextracranial segments of the internal carotid artery, basilar artery, and bilateral vertebral artery occlusion) confirmed by vessel imaging (including computed tomography angiography \\[CTA\\] or magnetic resonance angiography \\[MRA\\]), or scheduled for endovascular treatment (including mechanical thrombectomy, intra-arterial thrombolysis, and angioplasty).\n2. Intracranial hemorrhage confirmed by imaging post-thrombolysis.\n3. Definite or suspected cardioembolic stroke.\n4. Stroke caused by other determined causes, including nonatherosclerotic vasculopathies (moyamoya disease, artery dissection, arteritis), hypercoagulable states, or hematological disorders.\n5. Use of antiplatelet therapy within one week prior to stroke onset, novel anticoagulant drugs within 48 hours prior to stroke onset, or treatment with warfarin with an international normalized ratio (INR)\\>1.7.\n6. Prior history of moderate or severe ischemic stroke events with residual neurological disability.\n7. Pre-stroke mRS score \\> 1.\n8. Severe consciousness disturbance with NIHSS item 1a (level of consciousness) ≥ 2 points.\n9. Post-thrombolysis imaging indicates an infarct area larger than 1\u002F2 responsible artery supply area.\n10. Known contraindications for antiplatelet therapy, such as coagulation disorders, or systemic bleeding\n11. History of aspirin allergy.\n12. Anticipated indications for anticoagulant therapy during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid syndrome, hypercoagulable state)\n13. Presence of malignant tumors, chronic hemodialysis, severe renal insufficiency (GFR \\\u003C 30 mL\u002Fmin or serum creatinine \\> 220 μmol\u002FL \\[2.5 mg\u002FdL\\]), severe hepatic insufficiency (serum alanine aminotransferase \\[ALT\\] \\>2 times the upper limit of normal, or serum aspartate aminotransferase \\[AST\\] \\>2 times the upper limit of normal), severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification Class III or IV)\n14. Severe non-cardiovascular complications with an expected survival of less than 6 months.\n15. Unavailability for follow-up.\n16. Presence of dementia, psychiatric disorders, or other known neurological conditions that complicate follow-up.\n17. Current participation in another therapeutic study with ongoing treatment and follow-up.\n18. Other conditions that make the patient unsuitable for participation in the study as determined by the investigator.",{"count":227,"type":20},1184,[23],"Stroke is the second leading cause of death worldwide, and ischemic stroke is the most frequent type. Intravenous thrombolysis with recombinant tissue plasminogen activator within 4.5 hours of symptom onset is the most effective therapy for patients with acute ischemic stroke. However, ischemic stroke progression and early reocclusion are not an uncommon phenomenon in patients after intravenous thrombolysis, resulting in neurological deterioration, which is associated with unfavorable functional outcomes. The underlying mechanism mainly involves the augmented platelet activation, triggered by the activated coagulation cascade during thrombolysis, which peaks within 2 hours of initiating rt-PA administration. Therefore, early antiplatelet therapy following intravenous thrombolysis represents a promising therapeutic approach to prevent neurological deterioration and improve the functional outcome of patients treated with intravenous thrombolysis.\n\nCurrently, guidelines recommend initiating antiplatelet therapy 24 hours after intravenous thrombolysis due to the potential risk of increased bleeding. The safety and efficacy of early antiplatelet treatment following intravenous thrombolysis in patients with acute ischemic stroke remain clear.\n\nThe study aims to test the hypothesis that in patients with acute ischemic stroke treated with intravenous thrombolysis, early administration of oral aspirin will improve functional outcomes without increasing the risk of intracranial hemorrhage.",[172,28],[232,233,234,117],"Acute ischemic stroke","Intravenous thrombolysis","Early neurological deterioration","2025-12-14",{"date":237,"type":33},"2025-12-19",{"date":239,"type":33},"2024-11-07",{"date":241,"type":20},"2026-03",{"name":243,"class":40},"Capital Medical University",71,{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":266,"locationsCount":41},"100599213","research-on-binaural-synchronous-vagus-nerve-regulation-of-sensorimotor-disorders-after-cerebral-infarction-100599213","NCT07081568","Research on Binaural Synchronous Vagus Nerve Regulation of Sensorimotor Disorders After Cerebral Infarction","Inclusion Criteria:\n\n* Patients with first-episode ischemic stroke within 7 to 14 days of onset;\n* Be over 18 years old;\n* The skin at the irritated area remains intact;\n* The informed consent form has been signed.\n\nExclusion Criteria:\n\n* Severe cognitive dysfunction (Mini-Mental State Examination≥19);\n* Peripheral limb movement limiting factors (fractures);\n* History of major neurological and mental disorders in the past;\n* Uncontrollable limb and facial muscle twitching, and spontaneous profuse sweating;\n* Intracranial shunt pumps, metal implants",{"count":252,"type":20},40,[53],"The aim of this study is to determine the efficacy and safety of binaural synchronous vagus nerve regulation in the treatment of patients with sensory and motor dysfunction after cerebral infarction through a randomized controlled clinical study, and to provide high-quality evidence support for binaural synchronous vagus nerve regulation in the treatment of cerebral infarction.",[28],[112,257,258,259],"Transcutaneous Auriculai Vagus Nerve Stimulation","Rehabilitation for Cerebral Infarction","Neuromodulation","2025-10-02",{"date":262,"type":33},"2025-10-07",{"date":264,"type":33},"2025-06-25",{"date":154,"type":20},{"name":267,"class":40},"Nanchang University Affiliated Rehabilitation Hospital",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":275,"targetDuration":277,"studyType":278,"phases":4,"briefSummary":279,"conditions":280,"keywords":284,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":41},"100310212","stroke-recovery-initiative---registry-for-stroke-research-studies-100310212","NCT03318432","Stroke Recovery Initiative - Registry for Stroke Research Studies","Stroke Recovery Initiative - Stroke Registry","* 18 years of age or older\n* Have suffered a stroke\n* Have ongoing symptoms as a result of the stroke",{"count":276,"type":20},60000,"5 Years","OBSERVATIONAL","The Stroke Recovery Initiative is a nation-wide participant recruitment registry that connects people who have had a stroke with researchers who are working to develop new approaches to improve recovery after stroke.",[60,281,112,282,283,64,28,65,83],"Acute Stroke","Hemorrhagic Stroke","Subarachnoid Hemorrhage",[60,281,112,282,64,28,65,83,285],"Stroke Recovery","2025-09-26",{"date":260,"type":33},{"date":289,"type":33},"2013-02-09",{"date":291,"type":20},"2028-09",{"name":293,"class":40},"University of California, San Francisco",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":305,"conditions":306,"keywords":312,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":41},"100475904","phase-3-evaluation-of-low-dose-colchicine-and-ticagrelor-in-prevention-of-ischemic-stroke-in-patients-with-stroke-due-to-atherosclerosis-100475904","NCT05476991","Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis","Reducing Inflammation in Ischemic Stroke With Colchicine, and Ticagrelor in High-risk Patients-extended Treatment in Ischemic Stroke","RIISC-THETIS","Inclusion criteria:\n\nPatient should have the following:\n\nPatient with:\n\n1. Cerebral infarction (CI) proven by neuro-imaging (MRI or head-CT), immediately once the neurologic deficit is stabilized (investigator judgement) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event (TIA with documented ischemic lesion (MRI or CT) in the appropriate area corresponding to the symptoms will be considered CI, following the current definition)\n2. Or TIA lasting more 10 minutes or more (with motor symptoms or aphasia\u002Fdysarthria or visual defect), with total resolution and no brain lesion on neuro-imaging (TIA) and with ipsilateral carotid stenosis that was revascularized (endarterectomy or stenting) or with ipsilateral, potentially causal intracranial stenosis ≥70%) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event\n3. and documented atherosclerotic stenosis:\n\n   1. presence of carotid atherosclerotic stenosis (on the basis of carotid duplex, CTA, MRA, XRA - only the report will be required to document atherosclerotic disease) ipsilateral to the cerebral ischemic symptoms (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)\n   2. or presence of atherosclerotic stenosis of another cerebral artery (documented vertebral artery stenosis, basilar artery stenosis, other intracranial artery stenosis) ipsilateral to the ischemic area (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)\n   3. or presence of atherosclerotic disease of the aortic arch with a plaque ≥4mm in thickness with or without superimposed thrombus, or a plaque \\\u003C4 mm with a superimposed mobile thrombus (detected by transesophageal echocardiography or CT angiography)\n4. with no clear indication of colchicine treatment (gout, Mediterranean fever) and with an indication to long-term antiplatelet therapy (no clear indication to oral anticoagulant)\n5. age equal or above 18\n6. Rankin score less than ≤4 (ranges from 0 to 6, with 0 indicating no symptoms, 1 no disability, 2 to 3 needing some help with daily activities, 4 to 5 dependent or bedridden, and 6 death),\n7. fully informed and signed inform consent\n8. with social security number.\n9. medical examination before the participation to the research\n10. Under contraception in case of childbearing potential (highly effective: 1) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation et 2) progestogen-only).\n11. Pregnancy test for women of childbearing potential\n\nExclusion Criteria:\n\n1. Colchicine treatment needed (e.g., gout, Mediterranean fever)\n2. Hypersensitivity to ticagrelor or any of the excipients.\n3. Hypersensitivity to colchicine or any of the excipients.\n4. Major digestive disorders (chronic diarrhea, inflammatory disease of the digestive tract as uncontrolled ulcerative colitis or active Crohn disease)\n5. Immunosuppression, medullary aplasia\n6. Active chronic inflammatory disease, chronic active infection, evolving cancer\n7. Hemodynamic instability (need for amines for more than 24 hours, circulatory assistance)\n8. A recent severe sepsis (7 days) or all recent acute reaches\n9. Chronic treatment (for more than 6 months) with corticosteroids or NSAIDs (or repeated high-dose intake for less than 7 days).\n10. Anticipated concomitant oral or intravenous therapy with strong CYP3A4 inhibitors or CYP3A4 substrates than cannot be stopped for the course of the course of this study\n11. CI\u002FTIA due to arterial dissection (as documented following the judgment of the investigator) or due to cardiac source of embolism without documented atherosclerotic disease (e.g., mitral stenosis or endomyocardial fibrosis, endocarditis) a patient with atrial fibrillation, or with a history of myocardial infarction, or with calcified aortic stenosis will be eligible if the above inclusion criteria are also met\\]\n12. Indication to long-term oral anticoagulant treatment (e.g., atrial fibrillation)\n13. Symptomatic hemorrhagic stroke (the mere presence of asymptomatic cerebral hemosiderin deposits -so called \"microbleedings\" - on gradient echo imaging is not an exclusion criteria)\n14. Active pathological bleeding\n15. Uncontrolled hypertension (investigator judgement)\n16. Follow-up visit impossible or anticipated bad compliance.\n17. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits..\n18. Anticipated pregnancy at time of enrollment in the study\n19. Breastfeeding woman\n20. Patients participating in another pharmaco therapeutic program with an experimental therapy that is known to affect the ticagrerlor, colchicine or aspirine therapy.\n21. Leukopenia \\\u003C3000\u002Fμl\n22. Patients with severe renal impairment (creatinine clearance \\\u003C 30 ml\u002Fmin)\n23. Patients with severe hepatic impairment\n24. Prohibited treatments: All treatments contraindicated during the use of colchicine and\u002For ticagrelor",{"count":303,"type":20},2800,[23],"REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.",[60,27,307,308,309,310,311,28],"Atherosclerosis","Myocardial Infarction","Coronary Syndrome","TIA","Cardiac Disease",[60,313,307,117,314],"Colchicine","Ticagrelor","2025-09-01",{"date":317,"type":33},"2025-09-08",{"date":319,"type":33},"2023-05-17",{"date":321,"type":20},"2027-09-01",{"name":132,"class":40},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":344,"locationsCount":346},"100603239","phrenic-nerve-stimulation-for-reducing-ventilation-duration-in-acute-cerebral-infarction-a-multicenter-randomized-controlled-trial-100603239","NCT07133932","Phrenic Nerve Stimulation for Reducing Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial","Transcutaneous Electrical Phrenic Nerve Stimulation for Reducing Mechanical Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial","EDP-VENT","Inclusion Criteria:\n\n* age ≥ 18 years old\n* no gender restrictions\n* patient diagnosed with acute cerebral infarction (within 30 days of onset) through cranial CT or MRI\n* duration of mechanical ventilation ≥ 24 hours\n* patient or their legal guardian agrees to participate in the study and signs an informed consent form\n\nExclusion Criteria:\n\n* there are other significant conditions that affect diaphragm function, such as severe malnutrition, irreversible respiratory pump failure caused by medullary or cervical cord injury, and irreversible damage to the phrenic nerve\n* significant agitation cannot be combined with transcutaneous electrical phrenic nerve stimulation\n* severe skin damage or infection at the electrode placement site\n* previous presence of severe lung disease (such as severe COPD, interstitial lung disease, pulmonary embolism, etc.), severe heart failure (NYHA Class IV)\n* sepsis or shock requiring high-dose vasopressors\n* the terminal state of the disease or expected survival period does not exceed 7 days\n* pacemaker implantation\n* pregnant or lactating women\n* patients whose family members express their willingness to withdraw for treatment",{"count":332,"type":20},590,[53],"The goal of this clinical trial is to learn if non-invasive phrenic nerve stimulation works in adult acute cerebral infarction participants undergoing mechanical ventilation. It will also learn about the safety of non-invasive phrenic nerve stimulation. The main questions it aims to answer are：\n\n1. Can non-invasive phrenic nerve stimulation shorten the duration of ventilator use and improve long-term prognosis?\n2. What medical problems do participants have when taking non-invasive phrenic nerve stimulation? Researchers will compare non-invasive phrenic nerve stimulation to a sham stimulation to see if non-invasive phrenic nerve stimulation works.\n\nParticipants will:\n\n1. Receive 14 days of non-invasive phrenic nerve stimulation or sham stimulation\n2. Visit the clinic or call for follow-up at 90 days of onset",[28,336,337,338],"Mechanical Ventilation","Acute Cerebrovascular Accident","Adult","2025-08-13",{"date":341,"type":33},"2025-08-21",{"date":315,"type":20},{"date":154,"type":20},{"name":345,"class":40},"Xuanwu Hospital, Beijing",9,{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":354,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":356,"conditions":357,"keywords":362,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":4},"100601819","development-and-validation-of-a-prognostic-model-for-neurocritical-patients-using-multimodal-brain-monitoring-100601819","NCT07115459","Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring","Protocol for Developing and Validating a Multimodal Brain Monitoring-Based Prognostic Model for Neurocritical Patients: A Prospective, Observational, Multicenter Cohort Study","Inclusion Criteria:\n\n1. Aged 18-80 years, no gender restrictions.\n2. Diagnosed with acute brain injury (ABI), including one of the following: large cerebral infarction, supratentorial large-volume intracerebral hemorrhage, subarachnoid hemorrhage, or severe traumatic brain injury, with imaging evidence (CT or MRI) supporting the diagnosis.\n3. On ICU admission, Glasgow Coma Scale (GCS) eye response = 1 (no eye opening) and motor score ≤ 5 (does not follow commands); or within 48 hours, neurological deterioration with no eye opening and motor score reduced to ≤ 5 (total GCS score ≤ 8).\n4. Able to undergo continuous multimodal monitoring, with an expected ICU stay of ≥72 hours.\n5. Informed consent signed by the family or legal representative.\n\nExclusion Criteria:\n\n1. Confirmed brain death on admission or imaging showing irreversible brain herniation.\n2. Severe trauma unrelated to brain injury (e.g., multiple fractures, spinal cord injuries, or visceral rupture) that may interfere with brain function monitoring or outcome assessment.\n3. Pre-existing severe neurological disorders such as epilepsy, severe encephalopathy, or chronic intracranial conditions (e.g., brain tumors or hydrocephalus).\n4. Inability to perform multimodal monitoring due to technical issues (e.g., equipment failure or sensor installation problems).\n5. Predicted survival time \\\u003C24 hours after admission, or family members choose to withdraw treatment.\n6. Refusal to participate in the study by the patient or their legal representative.",{"count":355,"type":20},167,"This study aims to develop and validate a prognostic model for neurocritical patients using multimodal brain monitoring data. By combining data from various monitoring techniques such as EEG, TCD, and NIRS, this model will help predict 90-day outcomes (awake, comatose, or deceased) and support personalized treatment decisions. The study is observational and involves no experimental interventions.",[358,359,28,360,283,361],"Acute Brain Injury Coma","Neurocritical Care","Intracranial Hemorrhages","Severe Traumatic Brain Injury",[363,364],"Multimodal Brain Monitoring","Prognostic Model","2025-08-03",{"date":367,"type":33},"2025-08-11",{"date":369,"type":20},"2025-08-15",{"date":371,"type":20},"2026-11-15",{"name":373,"class":40},"Xiangya Hospital of Central South University",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":21,"phases":384,"briefSummary":385,"conditions":386,"keywords":391,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":4},"100550486","phase-3-interleukin-6-receptor-inhibition-for-symptomatic-intracranial-atherosclerosis-100550486","NCT06447701","Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis","Effect of Interleukin-6 Receptor Inhibition for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerosis: a Double-blind, Randomized, Placebo-controlled Trial","IRIS-sICAS","Inclusion Criteria:\n\n* Male or non-pregnant women with acute stroke symptoms aged over 18 years.\n* Patients having an ischemic stroke or a TIA prior to randomization (Patients having an acute ischemic stroke within 72 hours with NIHSS score≤5 at baseline, or patients having a TIA within 72 hours with Oxfordshire Community Stroke Project on the basis of age, blood pressure, clinical features, and duration of TIA symptoms (ABCD2) score≥4 at baseline).\n* The entry event is attributed to symptomatic atherosclerosis (50-99%) in an intracranial qualifying artery (intracranial carotid artery (C4-7), middle cerebral artery (M1), intracranial vertebral artery or basilar artery) confirmed by CT, MR angiography, or digital subtraction angiography.\n* Informed consent obtained from patients or their legal representatives.\n* Willing to be followed up as required by the clinical study protocol.\n\nExclusion Criteria:\n\n* Thrombolytic therapy or thrombectomy within 24 hours prior to enrollment.\n* Pre-stroke mRS score ≥ 2.\n* Combined or previous intracranial hemorrhage: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.\n* Any of the following unequivocal cardiac source of embolism: chronic or paroxysmal atrial fibrillation, sinus node dysfunction, mitral stenosis, prosthetic heart valves, endocarditis, left ventricular mural thrombus or valvular vegetation, myocardial infarction within three months, dilated cardiomyopathy, spontaneous echogenic defects in the left atrium or an ejection fraction of less than 30%.\n* Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus; any known vasculitic disease.\n* Extracranial stenosis ≥50%, subclavian arterial stenosis≥50% or subclavian steal syndrome.\n* Previous interventions for intracranial arterial stenosis.\n* Concurrent intracranial tumors, intracranial aneurysms or arteriovenous malformations\n* Neutrophil \\\u003C 2×10 9\u002FL.\n* Platelet \\\u003C 100×10 9\u002FL.\n* Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal.\n* Active infections including localized.\n* Evidence of HIV or hepatitis B positivity.\n* Positive tuberculosis-related tests.\n* Concurrent peptic ulcer, diverticulitis or inflammatory bowel disease.\n* Concurrent malignant tumors, recent bone marrow transplant or recent organ transplant.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite blood pressure control.\n* Known allergy to tocilizumab or excipients.\n* Use of immunosuppressive drugs or systemic use of antibiotics.\n* Received any live or live attenuated vaccine within 4 weeks prior to enrollment or plan to receive a live or live attenuated vaccine during the study.\n* History of demyelination or presence of neurological symptoms suggestive of demyelination.\n* Previously existing neurological or psychiatric disorders that could potentially confuse neurological function assessment.\n* An expected survival less than 90 days.\n* Participation in another interventional clinical study.\n* Patients unsuitable for enrollment in the clinical trial according to investigators decision making.",{"count":383,"type":20},486,[23],"IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.",[387,112,388,60,28,389,390],"Brain Diseases","Ischemia","Atherosclerosis of Artery","Atheroscleroses, Intracranial",[392,393,394,395],"Tocilizumab","Symptomatic intracranial atherosclerotic stenosis","Recurrence","Ischemic stroke","2025-07-24",{"date":398,"type":33},"2025-07-28",{"date":400,"type":20},"2025-10-30",{"date":402,"type":20},"2029-06-30",{"name":404,"class":40},"Zhujiang Hospital",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":413,"targetDuration":4,"studyType":21,"phases":414,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":41},"100570804","phase-2-a-dose-response-controlled-trial-of-bevifibatide-for-acute-ischemic-stroke-100570804","NCT06712004","A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke","Efficacy and Safety of Bevifibatide Citrate Injection in Patients With Acute Ischemic Stroke Without Large or Medium-Sized Vessel Occlusion: A Single-Center, Randomized, Double-Blind, Dose-Response Controlled Clinical Trial","BCAIS-I","Inclusion Criteria:\n\n* Any of the following presentations of acute ischemic stroke (AIS): ① Within 24 hours of time last known well and ineligible for intravenous thrombolysis (IVT) or endovascular treatment (EVT). ② More than 24 hours and less than 96 hours after time last known well but within 24 hours of ischemic stroke progression \\[worsening of ≥ 2 points on the NIHSS\\]; and ineligible for IVT or EVT without ICH confirmed by CT scan or MRI. ③ Treated with IVT followed by early neurological deterioration (worse NIHSS by ≥ 4 points) within the first 24 hours after IVT without ICH confirmed by CT scan or MRI. ④ Treated with IVT followed by no neurological improvement (Neurological improvement is defined as decrease in the NIHSS score by ≥ 2 points) from baseline within 4 to 24 hours after IVT without ICH confirmed by CT scan or MRI.\n* NIHSS score ≥ 3 immediately prior to trial entry.\n* Without visible large or medium intracranial vessel occlusion on CT angiography (CTA), MR angiography (MRA), or digital subtraction angiography (DSA). (Qualifying mechanisms are: 1. hypoperfusion caused by arterial stenosis; 2. the initial occluded large or medium artery spontaneously recanalized or recanalized with IVT before the vascular imaging performed; 3. multiple or single distal emboli from cardiac or other sources in arterial branches too small to visualized on CTA or MRA; 4. lacunar infarct due to small vessel occlusion).\n* Written informed consent obtained from patients or their legal representatives.\n\nExclusion Criteria:\n\n* CT or MR evidence of intracranial haemorrhage.\n* Pre-morbid disability with a mRS score ≥ 2.\n* Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%.\n* Planned treatment with dual antiplatelet therapy within 1week of the index stroke.\n* Any history of a primary or other intracerebral (parenchymal) haemorrhage (intraventricular, subarachnoid, subdural, epidural).\n* Any untreated or incompletely treated intracranial aneurysm, any intracranial vascular malformation or any intracranial tumour.\n* Currently pregnant or lactating, and those planned to conceive.\n* Subjects with positive urine HCG test results.\n* Known allergy to study medication or concomitant medications.\n* Gastrointestinal bleeding, urinary tract bleeding, or other major systemic haemorrhage within 30 days.\n* Any major surgery within 6 weeks of the index stroke.\n* History of heparin-induced thrombocytopenia.\n* Expected lifespan less than 3 months.\n* Pre-existing neurological or psychiatric disease that would confound the neurological functional outcome evaluations.\n* Any of the following laboratory tests: INR \\[International Normalized Ratio\\]\\>2.0, PT\\>1.3 times normal value, platelet count\\\u003C100 × 109\u002FL, Hb\\\u003C10g\u002Fdl.\n* Systolic pressure greater than 180 mmHg or diastolic pressure greater than 110 mmHg after aggressive treatment.\n* Severe renal insufficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin or serum creatinine \\> 220 μmol\u002FL \\[2.5 mg\u002Fdl\\]).\n* History of liver dysfunction (AST\u002FALT exceeding the upper limit of normal by more than twice) or cirrhosis.\n* Arterial tortuosity and\u002For other arterial diseases that prevent the expected internal thrombectomy device from reaching the target vessel.\n* Unlikely to be available for 90-day follow-up.\n* Current participation in another treatment clinical trial.\n* Other conditions that are not suitable for participation in the study.",{"count":252,"type":20},[415],"PHASE2","BCAIS-I is a single-center, randomized, double-blind, dose-response controlled clinical Trial, to preliminarily explore the efficacy of two different maintenance doses of bevifibatide citrate injection in improving 90-day neurological outcomes and the incidence of symptomatic intracranial hemorrhage in patients with acute ischemic stroke without large or medium-sized vessel occlusion, aiming to identify a dosing regimen that maintains therapeutic efficacy while minimizing the rates of symptomatic intracranial hemorrhage and serious adverse events, thereby providing dosing evidence for future large-scale randomized controlled trials.",[418,112,28,387],"Ischemic Stroke, Acute",[420,421,172],"Bevifibatide citrate injection","Dose-response controlled","2025-07-15",{"date":424,"type":33},"2025-07-17",{"date":426,"type":33},"2025-02-10",{"date":428,"type":20},"2025-12-01",{"name":404,"class":40},{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":438,"conditions":439,"keywords":440,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":41},"100596281","thrombus-analysis-of-ischemic-stroke-100596281","NCT07043413","Thrombus Analysis of Ischemic Stroke","TAOIST","Inclusion Criteria:\n\n* patients with acute ischemic stroke who had undergone endovascular thrombectomy\n\nExclusion Criteria:\n\n\\-",{"count":51,"type":20},"Patients with acute ischemic stroke who have undergone endovascular thrombectomy will be eligible to be included, and thrombus will be collected after obtaining informed consent. Enrolled patients will receive a comprehensive diagnostic evaluation and the best medical treatment according to recent stroke management guidelines. The mechanism of the stroke will be classified into atherosclerotic, cardiac embolism, others and unknown causes based on diagnostic workup. Patients will be monitored in an outpatient clinic for vascular events including stroke recurrence, death, and bleeding events, which will continue for up to two years after the initial stroke event. Thrombus information related to RNA expression patterns and histological characteristics will be analyzed to classify the stroke mechanism and predict future vascular events after the initial stroke.",[28],[441,442,443,444],"cerebral infarction","thrombus","stroke mechanism","prognosis","2025-06-20",{"date":447,"type":33},"2025-06-29",{"date":449,"type":33},"2022-01-25",{"date":451,"type":20},"2029-12-31",{"name":453,"class":40},"Seoul National University Hospital",{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":21,"phases":464,"briefSummary":465,"conditions":466,"keywords":471,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":482},"100415967","phase-2-effect-of-xenon-on-brain-injury-after-aneurysmal-subarachnoid-hemorrhage-100415967","NCT04696523","Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage","Effect of Xenon on Brain Injury, Neurological Outcome and Survival in Patients After Aneurysmal Subarachnoid Hemorrhage","Xe-SAH","Inclusion Criteria:\n\nTo be considered eligible to participate in this study, a SAH subject must meet the inclusion criteria listed below:\n\n1. Informed consent obtained from the next of kin or legal representative\n2. Aneurysmal subarachnoid hemorrhage visible on CTA or DSA.\n3. Deterioration of consciousness to Hunt-Hess 3-5\n4. Age of ≥ 18 years\n5. Intubated.\n6. GCS 3-12 obtained off neuromuscular blocking agents\n7. Xenon treatment can be started within 6 hours after onset of SAH symptoms\n\nExclusion Criteria:\n\nAn aSAH subject may not be enrolled in the trial if he\u002Fshe meets any one of the exclusion criteria below:\n\n1. Acute or chronic traumatic brain injury\n2. Maximum diameter of intracerebral hemorrhage \\> 2.5 cm\n3. Pneumothorax or pneumomediastinum,\n4. Acute lung injury requiring ≥ 60% FIO2 (fraction of inspired oxygen).\n5. Systolic arterial pressure \\\u003C 80 mmHg or mean arterial pressure \\\u003C 60 mmHg for over 30 min period\n6. Bilaterally fixed and dilated pupils\n7. Positive pregnancy test, known pregnancy, or current breast-feeding\n8. Neurological deficiency due to traumatic brain injury or other neurological illness\n9. Imminent death or current life-threatening disease\n10. Current enrollment in another interventional study\n11. The subject is known to have clinically significant laboratory abnormality, medical condition (such as decompensated liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the subject to participate in this clinical trial.\n12. Presence of implants or foreign bodies which are not known to be MRI safe",{"count":463,"type":20},160,[415],"An investigator-initiated clinical drug study\n\nMain Objective:\n\nTo explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH).\n\nPrimary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly higher in the xenon group than in the control group as assessed with the 1st magnetic resonance imaging (MRI).\n\nAfter confirmation of aSAH and obtaining a signed assent subjects will be randomized to the following groups:\n\nControl group: Standard of Care (SOC) group: Air\u002Foxygen and Normothermia 36.5-37.5°C; Xenon group: Normothermia 36.5-37.5°C +Xenon inhalation in air\u002Foxygen for 24 hours. Brain magnetic resonance imaging techniques will be undertaken to evaluate the effects of the intervention on white and grey matter damage and neuronal loss. Neurological outcome will be evaluated at 3, 12 and 24 months after onset of aSAH symptoms Investigational drug\u002Ftreatment, dose and mode of administration: 50±2 % end tidal concentration of inhaled xenon in oxygen\u002Fair.\n\nComparative drug(s)\u002Fplacebo\u002Ftreatment, dose and mode of administration: Standard of care treatment according to local and international consensus reports.\n\nDuration of treatment: 24 hours\n\nAssessments:\n\nBaseline data Information that characterizes the participant's condition prior to initiation of experimental treatment is obtained as soon as is clinically reasonable. These include participant demographics, medical history, vital signs, oxygen saturation, and concentration of oxygen administered.\n\nAcute data The collected information will contain quantitative and qualitative data of aSAH patients, as recommended by recent recommendations of the working group on subject characteristics, and including all relevant Common Data Elements (CDE) can be applied. Specific definitions, measurements tools, and references regarding each SAH CDE can be found on the weblink here: https:\u002F\u002Fwww.commondataelements.ninds.nih.gov\u002FSAH.aspx#tab=Data\\_Standards.",[467,468,64,28,469,470],"Subarachnoid Hemorrhage, Aneurysmal","Cerebral Injury","Cardiac Event","Cardiac Failure",[472],"xenon, neuroprotection, aneurysmal subarachnoid hemorrhage","2025-04-28",{"date":475,"type":33},"2025-05-01",{"date":477,"type":33},"2025-04-22",{"date":451,"type":20},{"name":480,"class":481},"Turku University Hospital","OTHER_GOV",7,{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":165,"enrollmentInfo":490,"targetDuration":4,"studyType":21,"phases":492,"briefSummary":493,"conditions":494,"keywords":497,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":41},"100550125","effects-of-myoelectric-biofeedback-on-upper-limb-function-in-post-stroke-patients-100550125","NCT06443008","Effects of Myoelectric Biofeedback on Upper Limb Function in Post-stroke Patients","Objective To Investigate the Effect of Myoelectric Biofeedback Therapy Combined With Comprehensive Rehabilitation Training on Upper Extremity Motor Function in Elderly Patients With Hemiplegia With Cerebral Infarction","Inclusion Criteria:\n\n1. Subject volunteered to participate in the experiment and signed informed consent\n2. Age ≥ 65 years old, no gender limit;\n3. Diagnosis of stroke patients;\n4. No other major cardiovascular diseases\n\nExclusion Criteria:\n\n1. Subject's poor compliance\n2. Subjects with skin allergies\n3. Those who do not meet the criteria for diagnosis and inclusion;\n4. People with severe consciousness disorders, severe dementia, speech disorders, etc. who are unable to communicate and describe the disease;\n5. can not cooperate as required, poor compliance;\n6. participants in other clinical trials;",{"count":491,"type":20},80,[53],"The purpose of this clinical trial is to investigate the effect of myoelectric biofeedback therapy on upper limb function in elderly patients with cerebral infarction, and to analyze the adjustment of stroke condition and quality of life.The main questions it aims to answer are:\n\n1. Does myoelectric biofeedback therapy promote the restoration of upper limb function in elderly patients with cerebral infarction?\n2. What medical problems do participants have with myoelectric biofeedback therapy?",[495,496,28],"Biofeedback","Rehabilitation",[498,499,500,441],"Rehabilitation treatment","upper extremity motor function","emg biofeedback","2025-02-14",{"date":503,"type":33},"2025-02-17",{"date":505,"type":33},"2024-07-01",{"date":507,"type":20},"2025-06-01",{"name":509,"class":40},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",{"id":511,"slug":512,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":517,"sex":16,"minAge":17,"maxAge":518,"enrollmentInfo":519,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":521,"conditions":522,"keywords":523,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":41},"100161324","serum-adiponectin-in-chinese-population-and-its-correlation-to-cardiovascular-and-cerebrovascular-diseases-100161324","NCT01372800","Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases","Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases","Inclusion Criteria:\n\n* available for 5 years of follow-up study\n\nExclusion Criteria:\n\n* Death caused other than cardiovascular and cerebralvascular diseases till the study ends\n* Floating Population\n* Pregnancy, lactation, or child bearing women\n* Tumor\n* Active hepatic disease or hepatic dysfunction, or AST\u002FALT \\> 1.5UNL\n* Severe renal dysfunction(Scr \\> 3 mg\u002Fdl or 264μmol\u002FL)\n* Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding",true,"85 Years",{"count":520,"type":20},30000,"Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.",[308,28],[524,525,526],"adiponectin","cardiovascular diseases","cerebrovascular diseases","2025-02-04",{"date":529,"type":33},"2025-02-07",{"date":531,"type":33},"2011-05-01",{"date":533,"type":20},"2036-10-01",{"name":535,"class":40},"Xijing Hospital",{"id":537,"slug":538,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":21,"phases":546,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":41},"100561221","phase-2-tirofiban-for-the-prevention-of-early-neurological-deterioration-after-intravenous-thrombolysis-in-acute-ischemic-stroke-100561221","NCT06587347","Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke","Effects of Tirofiban on Early Neurological Deterioration After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke: an Open-label, Multicenter, Randomized Controlled Trial","TREND-2","Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. Acute ischemic stroke treated with intravenous thrombolysis with alteplase or tenecteplase within 4.5 hours of onset or time last known well and can receive the study drug treatment within 3 hours of initiating intravenous thrombolysis.\n3. Residual NIHSS score ≥ 5 points at randomization (at least 1 hour after intravenous thrombolytic therapy).\n4. Post-thrombolysis imaging shows that the offending artery is consistent with moderate or severe intracranial atherosclerotic stenosis (within 50%\\~99%)\n5. Informed consent obtained from patients or their acceptable surrogates.\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage confirmed by imaging post-thrombolysis.\n2. Stroke caused by other determined causes, including moyamoya disease, artery dissection, arteritis, etc.\n3. Scheduled for or received endovascular treatment after onset.\n4. Definite or suspected cardioembolic stroke.\n5. Definite anticipation of developing indications for anticoagulant therapy during the study period (e.g., atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism, antiphospholipid syndrome, hypercoagulable state).\n6. Use of antiplatelet or anticoagulant therapy within one week pre-stroke.\n7. Pre-stroke mRS score ≥ 2.\n8. Severe consciousness disturbance with NIHSS item 1a (level of consciousness) \\>1 point at randomization.\n9. History of tirofiban allergy or its solvents.\n10. History of platelet count \\\u003C 100 × 109\u002FL caused by tirofiban.\n11. Major surgical operation within 6 weeks.\n12. Major systemic hemorrhage within 30 days;\n13. Determined coagulation disorders, platelet dysfunction, or platelet count \\\u003C 100\\*109\u002FL.\n14. Currently pregnant or lactating;\n15. Uncontrolled hypertension with systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg.\n16. Acute pericarditis or hemorrhagic retinopathy.\n17. Presence of malignant tumors, chronic hemodialysis, severe renal insufficiency (GFR \\\u003C 30 ml\u002Fmin or serum Cr \\> 220 μmol\u002FL (2.5 mg\u002Fdl)), severe hepatic insufficiency (serum ALT \\> 2 times the upper limit of normal, or serum AST \\> 2 times the upper limit of normal), severe heart failure (NYHA class III or IV).\n18. Severe non-cardiovascular complications with an expected survival of less than 6 months.\n19. Unavailability for follow-up.\n20. Presence of dementia, psychiatric disorders, or other known neurological conditions that complicate follow-up.\n21. Participated in this study in the past.\n22. Current participation in another therapeutic study with ongoing treatment and follow-up.\n23. Other conditions that are not suitable for participation in this study as determined by the investigator.",{"count":545,"type":20},302,[415,23],"A prospective, multicenter, randomized, controlled, open-label, blinded endpoint trial to evaluate the safety and efficacy of intravenous administration of tirofiban for preventing early neurological deterioration after intravenous thrombolysis in patients with acute ischemic stroke.",[281,418,28],[232,550,551,552,553],"Neurological deterioration","Stroke progression","intravenous thrombolysis","Antiplatelet therapy","2024-10-28",{"date":556,"type":33},"2024-10-29",{"date":558,"type":20},"2024-11-20",{"date":560,"type":20},"2026-06-30",{"name":243,"class":40},{"id":563,"slug":564,"hasResults":11,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":11,"sex":16,"minAge":569,"maxAge":165,"enrollmentInfo":570,"targetDuration":4,"studyType":21,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":4},"100558320","th-tl-xb-prescription-on-reprogramming-of-lipid-metabolism-and-endothelial-injury-for-cerebral-infarction-patients-100558320","NCT06549582","Th Tl Xb Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients","Effect of Taohong Tongluo Xiaoban Prescription on Reprogramming of Lipid Metabolism and Endothelial Injury for Cerebral Infarction Patients：a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. The CT\u002FMRI examination findings were consistent with the diagnosis of Western cerebral infarction, aligning with the TCM apoplexy diagnosis. Primary stroke occurred 35±5 days ago.\n2. The National Institutes of Health Stroke Scale (NIHSS) evaluates a range of scores from 4 to 24.\n3. Coronary atherosclerotic heart disease is confirmed through coronary CT angiography. Carotid artery ultrasonography is employed to ascertain the presence or absence of plaque formation, with stable plaques exhibiting predominantly high and uneven echogenicity, while unstable plaques displayed low echo or irregular hypoechoic regions.\n4. Age range: ≥35 years to ≤80 years.\n5. First onset requires; patients with previous diseases and no sequelae such as limb paralysis should not affect the NIHSS score, and the modified Rankin scale (mRS) score should be ≤1 point.\n6. Patient informed consent must be obtained.\n7. The criteria for the syndrome of phlegm and blood stasis are as follows: Main syndrome: hemiplegia, mouth and eyes skew, speech retarding or silent, sensation diminished or disappeared; Secondary syndrome: excessive sputum, fat tongue with teeth marks on the side, dark red tongue, sublingual vein blue or tortuous, tongue spots, white or thick greasy fur, pulse slippery.\n\n   \\-\n\nExclusion Criteria:\n\n1. subarachnoid hemorrhage, transient ischemic attack, or other intracranial lesions such as intracranial tumor, aneurysm, vascular malformation, cerebral cysticercosis, intracerebral schistosomiasis, encephalitis, meningitis, hydrocephalus, and sequelae of brain trauma; Nonatherosclerotic thrombotic cerebral infarction (e.g., cardiogenic embolism, hypercoagulability disorders, endovascular shedding and arteritis);\n2. onset occurring within a range of 30 to 40 days；\n3. The patient presents with limb motor dysfunction, emotional disorder, cognitive impairment, or speech impairment resulting from pre-existing conditions (e.g., surgery, trauma, or congenital disability) prior to the onset of cerebrovascular accident.\n4. Patients with severe cardiac disease, heart failure, liver or kidney failure, malignant tumors, gastrointestinal bleeding, severe infections, or uncontrolled diabetes are excluded from the study.\n5. Individuals currently participating in other clinical trials are not eligible for inclusion.\n6. Exclusion criteria include patients with mental illness, multiple body ulcers or joint contractures.\n7. Non-compliance with treatment by patients and their families is considered an exclusion criterion.\n8. Inability to comprehend the content of informed consent and inability to provide a signature on the informed consent form are also grounds for exclusion.\n9. . Pregnant and lactating women are excluded from participation.\n\n   \\-","35 Years",{"count":463,"type":20},[53],"This study is a prospective, open-label, randomized control trial. It is planning to include 160 cerebral infarction patients which will be randomized in a 1﹕1 fashion to receive Chinese herbal medicines combined basic medicine treatment, or to receive standard basic medicine treatment within 3 months after inclusion. Follow-up will be performed after the treatment for 3 months to evaluate the incidence and disability rates of limb impairment, language impairment, cognitive impairment, and emotional disorders. The primary outcome is modified Rankin Scale Score, which is measured by the overall distribution from 0 (no symptoms) to 6 (death). The secondary outcome include the Evaluation of Neurological Function Deficit score (National Institute of Health stroke scale scoring) and carotid atherosclerotic plaque score (Crouse scoring system for neck carotid atherosclerotic plaque scoring). Additional outcomes include laboratory indicator to analysis the reprogramming of lipid metabolism and endothelial Injury, Chinese medicine symptom and sign scoring system and biological indicators. The investigators will perform the intention-to-treat analysis for withdrawal and missing data, and estimate the health economic value.",[28,574,575,576,577],"Chinese Herbal Medicine","Clinical Trial","Lipid Metabolism Disorder","Endothelial Injury","2024-08-11",{"date":580,"type":33},"2024-08-14",{"date":582,"type":20},"2024-10",{"date":584,"type":20},"2026-12",{"name":586,"class":40},"Yan Zhu",{"id":588,"slug":589,"hasResults":11,"nctId":590,"briefTitle":591,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":617},"100513152","registry-of-multicenter-brain-heart-comorbidity-in-china-100513152","NCT05961748","Registry of Multicenter Brain-Heart Comorbidity in China","BHC-C","Inclusion Criteria:\n\n* age \\> 18 years old\n* Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \\[i.e., ACS\\], I46 (cardiac arrest), I48 (Atrial fibrillation\u002Fflutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).\n\nExclusion Criteria:\n\n·refuse to participate in the registry",{"count":595,"type":20},100000,"This study is a multi-center, prospective, registry study. This research was supported by the National Key Research and Development Program. To establish a domestic multi-center, large-scale \"brain-heart comorbidity\" dynamic database platform including clinical, sample database, image and other multi-dimensional information requirements, through the construction of a multi-center intelligent scientific research integration platform based on artificial intelligence.\n\nAny of newly diagnosed cardiovascular related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \\[i.e., ACS\\], I46 (cardiac arrest), I48 (Atrial fibrillation\u002Fflutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).\n\nThe data is stored on the brain-heart comorbidity warehouse via a physical server at the institution's data centre or a virtual hosted appliance. The brain-heart comorbidity platform comprises of a series of these appliances connected into a multicenter network. This network can broadcast queries to each appliance. Results are subsequently collected and aggregated. Once the data is sent to the network, it is mapped to a standard and controlled set of clinical terminologies and undergoes a data quality assessment including 'data cleaning' that rejects records which do not meet the brain-heart comorbidity quality standards. The brain-heart comorbidity warehouse performs internal and extensive data quality assessment with every refresh based on conformance, completeness, and plausibility (http:\u002F\u002F10.100.101.65:30080\u002Flogin).",[598,599,113,600,601,283,602,28,603,604,605,606,607],"Ischemic Heart Disease","Cardiac Arrest","Heart Failure","Aortic Diseases","Intracerebral Hemorrhage","Occlusion and Stenosis of Precerebral Arteries","Occlusion and Stenosis of Cerebellar Arteries","Cerebral Aneurysm","Moyamoya Disease","Arteriovenous Malformation of Cerebral Vessels","2023-09-16",{"date":610,"type":33},"2023-09-21",{"date":612,"type":33},"2012-01-01",{"date":614,"type":20},"2032-12-31",{"name":616,"class":40},"Beijing Tiantan Hospital",14,{"id":619,"slug":620,"hasResults":11,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":278,"phases":4,"briefSummary":627,"conditions":628,"keywords":630,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":4},"100494320","in-the-real-world-study-the-efficacy-and-adverse-reactions-of-ticagrelor-on-ischemic-cerebrovascular-disease-100494320","NCT05716646","In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease","Real-world Study on the Efficacy and Safety of Ticagrelor in the Treatment of Ischemic Cerebrovascular Disease","Inclusion Criteria:\n\n1. Female or male aged ≥ 18 years.\n2. Clinically diagnosed as ischemic cerebrovascular disease.\n3. Take ticagelor for antiplatelet therapy.\n4. Provision of informed consent.\n\nExclusion Criteria:\n\n1. Head CT or MRI suggests the presence of intracranial hemorrhagic disease.\n2. People with tumors and other serious systemic diseases.\n3. Allergy to ticagelor.",{"count":626,"type":20},50,"This is a forward-looking, open, one-arm, and real clinical trial world. The researchers plan to recruit at least 50 qualified patients. The main purpose of this study is to establish a population pharmacokinetic model of ticagrelor , explore the correlation between its blood concentration and the events of ischemia and the adverse effects of hemorrhage, and evaluate the effectiveness and safety of ticagrelor in the treatment of ischemic cerebrovascular disease.",[28,60,57,629],"Ischemic Cerebrovascular Disease",[631,314],"Vascular Diseases","2023-01-29",{"date":634,"type":33},"2023-02-08",{"date":636,"type":20},"2023-04",{"date":638,"type":20},"2028-12",{"name":640,"class":40},"Qianfoshan Hospital"]